AJANTPHARM.NS Balance Sheet
Ajanta Pharmaceuticals Ltd.
Profit & Loss Balance Sheet Cash Flow
Balance Sheet · 4 years on file
(FY2022-23 to FY2025-26)
· fetched 2026-08-23 21:33
| Line item | FY2022-23 | FY2023-24 | FY2024-25 | FY2025-26 | Source (XBRL element) |
|---|---|---|---|---|---|
| Property, Plant and Equipment | ₹1,407.83 Cr. | ₹1,384.13 Cr. | ₹1,624.87 Cr. | ₹1,726.35 Cr. | PropertyPlantAndEquipment |
| Capital Work-in-Progress | ₹209.47 Cr. | ₹256.45 Cr. | ₹176.27 Cr. | ₹258.05 Cr. | CapitalWorkInProgress |
| Goodwill | ₹0.00 Cr. | ₹0.00 Cr. | ₹0.00 Cr. | ₹0.00 Cr. | Goodwill |
| Other Intangible Assets | ₹88.61 Cr. | ₹95.06 Cr. | ₹137.15 Cr. | ₹140.60 Cr. | OtherIntangibleAssets |
| Non-current Investments | ₹25.10 Cr. | ₹18.58 Cr. | ₹25.24 Cr. | ₹28.50 Cr. | NoncurrentInvestments |
| Other Non-current Assets | ₹5.32 Cr. | ₹9.44 Cr. | ₹12.71 Cr. | ₹69.33 Cr. | OtherNoncurrentAssets |
| Total Non-current Assets | ₹1,845.02 Cr. | ₹1,907.47 Cr. | ₹2,171.92 Cr. | ₹2,419.41 Cr. | NoncurrentAssets |
| Inventories | ₹815.63 Cr. | ₹828.36 Cr. | ₹903.85 Cr. | ₹938.54 Cr. | Inventories |
| Trade Receivables | ₹1,056.90 Cr. | ₹1,246.84 Cr. | ₹1,182.74 Cr. | ₹1,853.88 Cr. | TradeReceivablesCurrent |
| Cash and Cash Equivalents | ₹329.83 Cr. | ₹129.49 Cr. | ₹175.12 Cr. | ₹103.26 Cr. | CashAndCashEquivalents |
| Current Investments | ₹510.27 Cr. | ₹330.05 Cr. | ₹438.71 Cr. | ₹559.85 Cr. | CurrentInvestments |
| Other Current Assets | ₹91.61 Cr. | ₹133.07 Cr. | ₹123.30 Cr. | ₹267.73 Cr. | OtherCurrentAssets |
| Total Current Assets | ₹2,825.18 Cr. | ₹2,722.07 Cr. | ₹2,829.70 Cr. | ₹3,735.43 Cr. | CurrentAssets |
| Total Assets | ₹4,679.02 Cr. | ₹4,638.39 Cr. | ₹5,014.95 Cr. | ₹6,154.84 Cr. | Assets |
| Equity Share Capital | ₹25.27 Cr. | ₹25.27 Cr. | ₹25.07 Cr. | ₹25.07 Cr. | EquityShareCapital |
| Other Equity | ₹3,362.72 Cr. | ₹3,542.09 Cr. | ₹3,765.22 Cr. | ₹4,502.02 Cr. | OtherEquity |
| Equity Attributable to Owners | ₹3,387.99 Cr. | ₹3,567.36 Cr. | ₹3,790.29 Cr. | ₹4,527.09 Cr. | EquityAttributableToOwnersOfParent |
| Non-controlling Interests | ₹0.00 Cr. | ₹0.00 Cr. | N/A | ₹0.00 Cr. | NonControllingInterest |
| Total Equity | ₹3,387.99 Cr. | ₹3,567.36 Cr. | ₹3,790.29 Cr. | ₹4,527.09 Cr. | Equity |
| Long-term Borrowings | ₹1.25 Cr. | ₹0.00 Cr. | ₹0.00 Cr. | ₹0.00 Cr. | BorrowingsNoncurrent |
| Total Non-current Liabilities | ₹151.75 Cr. | ₹175.27 Cr. | ₹228.56 Cr. | ₹212.00 Cr. | NoncurrentLiabilities |
| Short-term Borrowings | ₹0.18 Cr. | ₹1.49 Cr. | ₹2.59 Cr. | ₹211.99 Cr. | BorrowingsCurrent |
| Trade Payables | ₹422.77 Cr. | ₹463.20 Cr. | ₹454.20 Cr. | ₹544.30 Cr. | TradePayablesCurrent |
| Other Current Liabilities | ₹23.15 Cr. | ₹59.73 Cr. | ₹91.12 Cr. | ₹119.00 Cr. | OtherCurrentLiabilities |
| Total Current Liabilities | ₹1,139.28 Cr. | ₹895.25 Cr. | ₹996.10 Cr. | ₹1,415.75 Cr. | CurrentLiabilities |
| Total Equity and Liabilities | ₹4,679.02 Cr. | ₹4,638.39 Cr. | ₹5,014.95 Cr. | ₹6,154.84 Cr. | EquityAndLiabilities |
Every figure above is the exact value of the named XBRL element from AJANTPHARM.NS's cached filing for that year — nothing here is estimated or backfilled. A company shows one column per year StockProof actually has data for — never padded with blank years. Rows shown as N/A are genuinely not disclosed under that year's filing format (see peer comparison for how other Healthcare companies compare).